333 related articles for article (PubMed ID: 35447888)
1. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
2. Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer.
Sreekumar A; Saini S
Front Cell Dev Biol; 2023; 11():1075707. PubMed ID: 36711033
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.
Akoto T; Bhagirath D; Saini S
Cancer Drug Resist; 2020; 3(4):804-818. PubMed ID: 33426506
[TBL] [Abstract][Full Text] [Related]
4. Treatment-induced neuroendocrine prostate cancer and
Wishahi M
World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
7. Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients.
Bhagirath D; Dahiya R; Majid S; Tabatabai ZL; Saini S
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31814621
[TBL] [Abstract][Full Text] [Related]
8. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
Patel GK; Chugh N; Tripathi M
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
[TBL] [Abstract][Full Text] [Related]
10.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
12. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
[TBL] [Abstract][Full Text] [Related]
13. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
14. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
Naidoo M; Levine F; Gillot T; Orunmuyi AT; Olapade-Olaopa EO; Ali T; Krampis K; Pan C; Dorsaint P; Sboner A; Ogunwobi OO
Front Cell Dev Biol; 2021; 9():647485. PubMed ID: 34386489
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
19. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.
Santoni M; Conti A; Burattini L; Berardi R; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R
Biochim Biophys Acta; 2014 Dec; 1846(2):630-7. PubMed ID: 25450825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]